An evaluation of the effect of unoprostone isopropyl 0.15% on ocular hemodynamics in normal-tension glaucoma patients.
BACKGROUND
Because intraocular pressure-lowering agents should have a good safety profile with regard to ocular hemodynamics, the innocuousness of unoprostone isopropyl 0.15% with regard to ocular hemodynamics in vasospastic patients with normal-tension glaucoma was assessed in a pilot study.


METHODS
Corneal temperature as a parameter of ocular blood flow and choroidal and optic nerve blood flow as assessed by means of laser Doppler flowmetry techniques were evaluated in 12 vasospastic normal-tension glaucoma patients in a prospective, randomized, observer-masked, two-period crossover, placebo-controlled pilot trial.


RESULTS
Statistical analysis in 2 x 2 two-way analysis of variance models with two treatments (placebo and unoprostone isopropyl) and two assessments (baseline and after 1 week of treatment) as within-subject factors disclosed a lack of difference between eyes, between the treatment (placebo/unoprostone isopropyl) periods, and between baseline and after 1 week of treatment in corneal temperature, choroidal blood flow, and optic nerve blood flow. The differences between the results at baseline and after 1 week of treatment in these parameters were not significantly different between the placebo treatment period and the unoprostone isopropyl treatment period, and this was comparable in fellow eyes for all the parameters.


CONCLUSIONS
Unoprostone isopropyl did not induce any alterations in ocular hemodynamics in this pilot study with vasospastic normal-tension glaucoma patients.
Beano
F
F
University Eye Clinic Basel, PO Box, 4012 Basel, Switzerland.
Orgül
S
S
Stümpfig
D
D
Gugleta
K
K
Flammer
J
J
D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001783:Blood Flow Velocity / Q000187:drug effects; D001831:Body Temperature / Q000502:physiology; D002829:Choroid / Q000098:blood supply*; D003315:Cornea / Q000502:physiology; D018592:Cross-Over Studies; D015237:Dinoprost / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology*; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D017078:Laser-Doppler Flowmetry; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D009900:Optic Nerve / Q000098:blood supply*; D010865:Pilot Projects; D011446:Prospective Studies
D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; C072630:isopropyl unoprostone; D015237:Dinoprost